<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564365</url>
  </required_header>
  <id_info>
    <org_study_id>2020-09-22</org_study_id>
    <nct_id>NCT04564365</nct_id>
  </id_info>
  <brief_title>The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Influence of Beta-Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of beta blockers after acute myocardial infarction is a core component of drug&#xD;
      therapy, but evidence is primarily derived from patients who did not receive reperfusion&#xD;
      therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta&#xD;
      blockers in patients with acute myocardial infarction has been questioned, particularly in&#xD;
      patients without reduced heart failure/ejection fraction after acute myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2019</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>the median time of 8 months</time_frame>
    <description>all-cause mortality</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>with beta-blocker</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>without beta-blocker</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta-blocker</intervention_name>
    <description>To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction</description>
    <arm_group_label>with beta-blocker</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient had normal left ventricular ejection fraction (LVEFâ‰¥50%) after acute myocardial&#xD;
        infarction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The diagnosis of acute myocardial infarction was clear and the left ventricular&#xD;
             ejection fraction was normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of heart failure Died in hospital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongying Zhang</last_name>
      <phone>+8613608398395</phone>
      <email>zdy.chris@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Dongying Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>left ventricular ejection fraction</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>beta-blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

